That's an Abbott Laboratories designation, from whose website I inquired as to its availability, yesterday. No response yet.
> Abbott scientists are currently researching ABT-594, an investigational > > compound for pain. The non-opioid, non-NSAID > > (Non-Steroidal Anti-Inflammatory) compound belongs to a new class of drugs > > called cholinergic channel modulators, which affect acetylcholine receptors > > to stop pain signals to the brain. Pre-clinical studies are promising, > > with ABT-594 exhibiting morphine-like efficacy. > 10/02 > http://abbott.com/innovation/products.html > ========================================== > The big question remains whether ABT-594 has addicting traits. > > Because nicotine which is very addictive, is so similar in structure to > > ABT-594 it seems a very possible side effect... An answer should come in > > a few months when the European safety trial results become available. > > Many lives may have hope as a result of this creation of ABT-594... > > and yet strangely enough, this source of achievement comes from a frog. > > http://wwwchem.csustan.edu/chem4400/sjbr/strong98.htm > Ziconotide, derived from the ocean-dwelling cone snail, is currently in trial at UC San Diego, holds similar promise, but requires an internal pump/dispenser: > The hottest new drug for severe chronic pain is Ziconotide. > > This drug is derived from the paralyzing venom of Conus sea snails. > > The drug specifically targets the junctions where pain nerves enter the > > spine, effectively blocking the pain signal from entering the spinal tract > > carrying pain sensation to the brain. > > http://www.imagequest3d.com/pages/general/news/coneshell/coneshell.htm > Suzanne Daneshvari (858) 657-7037 is UCSD's Pain Management Study recruiter, and a joy to speak with. jr
